Influence of the antiallergic drug oxatomide and derivatives on membrane structures: Relation with inhibition of calcium influx in rat basophilic leukemia cells

Biochemical Pharmacology

Volumn 57, Issue 5, 1999, Pages 503-510

  Paulussen, Jeannette J C ^a   Fischer, Marcel J E ^a   Zuidam, Nicolaas J ^a   V Miltenburg, J Cees ^b   De Mol, Nico J ^a   Janssen, Lambert H M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiallergic drug; Calcium influx; Mast cells; Membrane; Store operated Ca2+ channels

Indexed keywords

ANTIALLERGIC AGENT; CALCIUM CHANNEL; CALCIUM ION; HISTAMINE H1 RECEPTOR ANTAGONIST; LIPOSOME; OXATOMIDE;

ANIMAL CELL; ANISOTROPY; ARTICLE; ARTIFICIAL MEMBRANE; CALCIUM TRANSPORT; CELL MEMBRANE; ERYTHROCYTE; FLUORESCENCE; HEMOLYSIS; LEUKEMIA CELL; MEMBRANE FLUIDITY; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; RAT;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; CALCIUM; CALORIMETRY, DIFFERENTIAL SCANNING; CATTLE; CELL MEMBRANE; FLUORESCENCE POLARIZATION; HEMOLYSIS; HISTAMINE H1 ANTAGONISTS; LEUKEMIA, BASOPHILIC, ACUTE; LIPID BILAYERS; MEMBRANE FLUIDITY; PHOSPHATIDYLCHOLINES; PIPERAZINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033104223     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00317-7     Document Type: Article

References (32)

1. Church M.K., Gradidge C.F. Inhibition of histamine releases from human lung in vitro by antihistamines and related drugs. Br J Pharmacol. 69:1980;663-667.
2. De Clerck F., Van Reempts J., Borgers M. Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents Actions. 11:1981;184-192.
3. Paulussen J.J.C., Fischer M.J.E., Roelofsen E.P.W., Horbach D.A., de Mol N.J., Janssen L.H.M. Oxatomide and derivatives as inhibitors of mediator release from a mast cell model. Drug Res. 46:1996;496-501.
4. Paulussen J.J.C., Fischer M.J.E., Kok-van Esterik J.A.E., Tiemessen R.C., de Mol N.J., Janssen L.H.M. Influence of the antiallergic drug oxatomide on the signal transduction mechanism in a mast cell model. Eur J Pharmacol. 312:1996;121-130.
5. Paulussen J.J.C., Fischer M.J.E., Roozendaal R., van der Heijden V.C., van Dijken P., de Mol N.J., Janssen L.H.M. Effects of oxatomide and derivatives on high affinity IgE receptor-activated signal transduction pathways in rat basophilic leukemia cells. Biochem Pharmacol. 56:1998;693-701.
6. Lau H.Y.A., Pearce F.L. Effects of antihistamines on isolated rat peritoneal mast cells and on model membrane systems. Agents Actions. 29:1990;151-161.
7. Fischer M.J.E., Paulussen J.J.C., Horbach D.A., Roelofsen E.P.W., van Miltenburg J.C., de Mol N.J., Janssen L.H.M. Inhibition of mediator release in RBL-2H3 cells by some H-1-antagonist-derived antiallergic drugs. Inflamm Res. 44:1995;92-97.
8. Chang E.Y., Zheng Y., Holowka D., Baird B. Alteration of lipid composition modulates Fc epsilon RI signalling in RBL-2H3 cells. Biochemistry. 34:1995;4376-4384.
9. Mason R.P. Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity. Biochem Pharmacol. 45:1993;2173-2183.
10. Mohr F.C., Fewtrell C. Depolarization of rat basophilic leukemia cells inhibits calcium uptake and exocytosis. J Cell Biol. 104:1987;783-792.
11. Litman B.J., Barenholz Y. Fluorescent probe Diphenyl hexatriene . Methods Enzymol. 81:1982;678-685.
12. Hansch C., Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. 1979;Wiley, New York.
13. Biltonen R.L., Lichtenberg D. The use of differential scanning calorimetry as a tool to characterize liposome preparations. Chem Phys Lipids. 64:1993;129-142.
14. Gennis R.B. The structures and properties of membrane lipids. Biomembranes. Molecular Structure and Function. 1989;64-65 Springer Verlag, New York.
15. Simon S.A., McIntosh T.J. A novel conformationally restricted protein kinase C inhibitor, Ro-31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli. Biochim Biophys Acta. 77:1984;169-172.
16. Thomas P.G., Verkleij A.J. The dissimilar interactions of the calcium antagonist flunarizine with different phospholipid classes and molecular species A differential scanning calorimetry study . Biochim Biophys Acta. 1030:1990;211-222.
17. Sainz M.C., Chantres J.R., Elorza B., Elorza M.A. DSC study of the action of phenylbutazone on DMPC and DPPC bilayers. Int J Pharmaceut. 89:1993;183-190.
18. Hwang S., Shen T.Y. Membrane effects of antiinflammatory agents. 2. Interaction of non-steroidal anti-inflammatory drugs with liposomes and purple membranes. J Med Chem. 24:1981;1202-1211.
19. Prendergast F.G., Haugland R.P., Callahan P.J. 1-[4-(Trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene Synthesis, fluorescence properties and use as a fluorescent probe of lipid bilayers . Biochemistry. 20:1981;7333-7338.
20. Kubina M., Lanza F., Cazenave J.P., Laustriat G., Kuhry J.G. Parallel investigations of exocytosis kinetics and membrane fluidity changes in human platelets with the fluorescent probe, trimethylammomio-diphenylhexatriene. Biochim Biophys Acta. 901:1987;138-146.
21. Borenstain V., Barenholz Y. Characterization of liposomes and other assemblies by multiprobe fluoresence polarization. Chem Phys Lipids. 64:1993;117-127.
22. Gennis R.B. Membrane dynamics and protein-lipid interactions. Biomembranes. Molecular Stucture and Functions. 1989;166-198 Springer Verlag, New York.
23. Berridge M.J. Capacitative calcium entry. Biochem J. 312:1995;1-11.
24. Aloui R., Gallet H., Biot N., Perrin-Fayolle M., Lagarde M., Pacheco Y. Behaviour of leukocyte membrane fluidity in presence of anaesthetic drugs. Comparison between allergic patients and control subjects. Gen Pharmacol. 24:1993;419-422.
25. Jain M.K., Wu N.M. Effect of small molecules on the dipalmitoyl lecithin liposomal bilayer. III. Phase transition in lipid bilayer. J Membr Biol. 34:1977;157-201.
26. Seeman P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev. 24:1972;583-655.
27. Hansch C., Dunn W.J. Linear relationships between lipophilic character and biological activity of drugs. J Pharm Sci. 61:1972;1-19.
28. Raves M.L., Kanters J.A., Tollenaere J.P. Structure of oxatomide monohydrate An anti-allergic drug . Acta Crystallogr. C48:1992;1712-1713.
29. Alberts B, Bray D, Lewis J, Raff M, Roberts K and Watson JD. In: Molecular Biology of the Cell 3rd Ed., p. 482. Garland Publishing Inc., New York, 1994.
30. Benvenuti C., Broggini M., Botta V., Valenti M., Broccali G., Dalbo L. Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. Biopharm Drug Dispos. 13:1992;495-502.
31. Awouters F., Niemegeers C.J.E., Janssen P.A., Janssen M., Vandenberk J., Kennis L., Van der Aa M., Van Heertum A. Oxatomide the prototype of a chemical series of compounds inhibiting both the release and the effects of allergic mediators . Temple D.L. Drugs Affecting the Respiratory System. 1980;179-208 American Chemical Society, Washington DC.
32. Kaise T., Ohmori K., Ukai K., Sakakura Y. Effect of oxatomide nasal spray on experimental allergic rhinitus in guinea pigs and rats. Int Arch Allergy Imm. 107:1995;576-580.